Evidence map›Paper›PMID 24585893›Full record

ArticleThe Journal of infectious diseases2014

Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection.

Sulggi A Lee, Elizabeth Sinclair, Vivek Jain, Yong Huang, Lorrie Epling, Mark Van Natta, Curtis L Meinert, Jeffrey N Martin, Joseph M McCune, Steven G Deeks and 3 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000168 (Studies of Ocular Complications of AIDS), which is not on this map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000168 completednot on this map

Studies of Ocular Complications of AIDS (SOCA)

TypeobservationalSponsorJohns Hopkins Bloomberg School of Public HealthRan1998 to 2013Enrolled2,392ConditionsHIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Harnessing CD8Frontiers in immunology · 2019
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Asymptomatic CMV Replication During Early Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower CD4/CD8 Ratio During HIV Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Sulggi A LeeUniversity of California San Francisco, San Francisco, California.
Elizabeth SinclairUniversity of California San Francisco, San Francisco, California.
Vivek JainUniversity of California San Francisco, San Francisco, California.
Yong HuangUniversity of California San Francisco, San Francisco, California.
Lorrie EplingUniversity of California San Francisco, San Francisco, California.
Mark Van NattaJohns Hopkins University, Baltimore, Maryland.
Curtis L MeinertJohns Hopkins University, Baltimore, Maryland.
Jeffrey N MartinUniversity of California San Francisco, San Francisco, California.
Joseph M McCuneUniversity of California San Francisco, San Francisco, California.
Steven G DeeksUniversity of California San Francisco, San Francisco, California.
Michael M LedermanCase Western Reserve University, Cleveland, Ohio.
Frederick M HechtUniversity of California San Francisco, San Francisco, California.
Peter W HuntUniversity of California San Francisco, San Francisco, California.
University of California, San Francisco · USJohns Hopkins University · USCase Western Reserve University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Studies of Ocular Complications of AIDS - Coordinating CenterU10EY008057 · NEI · JOHNS HOPKINS UNIVERSITY · PI VAN NATTA, MARK L · 1988 to 2012
$78.0M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
Clinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9M
Specimen Acquisition and Distribution CoreP01AI076174 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LANDAY, ALAN L · 2008 to 2012
$10.9M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
The impact of early antiretroviral therapy on HIV persistence and inflammationR01AI087145 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2009 to 2010
$1.6M
NCATS NIH HHS KL2 TR000143NCATS NIH HHS KL2TR000143NCATS NIH HHS UL1 TR001079NCRR NIH HHS UL1 RR024131NEI NIH HHS U10 EY008057NIAID NIH HHS K24 AI069994NIAID NIH HHS K24AI069994NIAID NIH HHS P01 AI076174NIAID NIH HHS P01AI076174NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI087145NIAID NIH HHS R21 AI087035NIAID NIH HHS R24 AI067039NIAID NIH HHS R56 AI100765NIAID NIH HHS R56AI100765NIAID NIH HHS T32 AI060530NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIMH NIH HHS P30 MH062246NIMH NIH HHS P30 MH62246
6 · The paper itself

Abstract

backgroundUnlike cytomegalovirus (CMV) infection and aging, human immunodeficiency virus (HIV) decreases the proportion of CD28(-)CD8(+) T cells expressing CD57. Whether this abnormality predicts mortality in treated HIV infection and can be reversed by early antiretroviral therapy (ART) remains unknown.

methodsWe sampled recently HIV-infected individuals (<6 months) and HIV-uninfected controls and compared longitudinal changes in the proportion of CD28(-)CD8(+) T cells expressing CD57 between those who initiated ART early (<6 months) vs later (≥2 years). We also assessed the relationship between this phenotype and mortality in a nested case-control study of ART-suppressed chronically infected individuals.

resultsCompared to HIV-uninfected controls (n = 15), individuals who were recently infected with HIV had lower proportions of CD28(-)CD8(+) T cells expressing CD57 (P < .001), and these proportions increased during ART. The early ART group (n = 33) achieved normal levels, whereas the later ART group (n = 30) continued to have lower levels than HIV-uninfected controls (P = .02). Among 141 ART-suppressed participants in the SOCA study, those in the lowest quartile of CD28(-)CD8(+) T cells expressing CD57 had 5-fold higher odds of mortality than those in the highest quartile (95% CI, 1.6-15.9, P = .007).

conclusionsAbnormally low proportions of CD28(-)CD8(+) T cells expressing CD57 predict increased mortality during treated HIV infection and may be reversed with early ART initiation.

Indexed as

AdultAnti-HIV AgentsCD28 AntigensCD57 AntigensCD8-Positive T-LymphocytesFemaleHIV InfectionsHumansLymphocyte CountMaleAnti-HIV AgentsCD28 AntigensCD57 Antigensagingantiretroviral therapyCD28CD57HIVimmune activationImmunosenescencemortality

Identifiers

PMID24585893
PMCPMC4110459
OpenAlexW2146166475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.